Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A Timeline of Rising Antisemitism in Australia - 2Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients
- 3What's your biological age? Experts explain the benefits and risks of at-home tests
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 5Middle East hotels hit pandemic-era lows amid Iran war
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- Claim that Israel opened 'sewage dam' into Gaza's main river undersells sanitation crisis
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Flu cases spiking this holiday season, CDC data shows
- From Exemplary to Current: Famous Rings Available
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
